Literature DB >> 11371998

Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation.

T Hashida1, S Masuda, S Uemoto, H Saito, K Tanaka, K Inui .   

Abstract

BACKGROUND: Living-donor liver transplantation (LDLT) and subsequent immunosuppressive therapy with tacrolimus have been cornerstones in the recovery of patients from end-stage liver failure, but there has been no critical dosage regimen for tacrolimus therapy, especially the initial dosage. In this study, we examined whether the absorptive barriers, multidrug resistance protein (MDR1), or cytochrome P450 IIIA4 (CYP3A4) are important pharmacokinetic factors for tacrolimus and are prognostic indicators for LDLT outcome.
METHODS: We used competitive polymerase chain reaction to evaluate the messenger ribonucleic acid (mRNA) expression levels of MDRL And Cyp3A4 in mucosal cells of the upper jejunum from a part of the Rroux-en- Y limb for biliary reconstruction during LDLT of recipients (n = 48). The tacrolimus dosage was started at an oral dose of 0.075 mg/kg every 12 hours and adjusted on the basis of its whole-blood trough level by use of a semiautomated microparticle enzyme immunoassay.
RESULTS: The mRNA expression level of MDR1 (r = -0.776), but not CYP3A4 (r = -0.094), was inversely related to the concentration/dose ratio of tacrolimus. High levels of MDR1, but not CYP3A4, were strongly associated with reductions in survival rates after LDLT with the Kaplan-Meier method and log-rank statistics (P =.020 and P =.135, respectively). With use of a Cox regression procedure, high levels of MDR1 (relative risk, 12.99; 95% confidence interval, 1.64-103.23), but not CYP3A4 (relative risk, 0.93; 95% confidence interval, 0.87-1.00) appeared to be a significant prognostic indicator for poor survival.
CONCLUSIONS: Intestinal MDR1 is not only a good probe with which to predict the interindividual variation in tacrolimus pharmacokinetics after LDLT but also a powerful prognostic indicator for the outcome of LDLT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371998     DOI: 10.1067/mcp.2001.115142

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  Prediction of glycylsarcosine transport in Caco-2 cell lines expressing PEPT1 at different levels.

Authors:  Megumi Irie; Tomohiro Terada; Masahiro Tsuda; Toshiya Katsura; Ken-Ichi Inui
Journal:  Pflugers Arch       Date:  2005-11-10       Impact factor: 3.657

2.  Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies.

Authors:  Franck Saint-Marcoux; Christiane Knoop; Jean Debord; Philippe Thiry; Annick Rousseau; Marc Estenne; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.

Authors:  Tomohiro Terada; Daiki Hira
Journal:  J Gastroenterol       Date:  2015-03-14       Impact factor: 7.527

4.  Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.

Authors:  Alex Ganetsky; Todd A Miano; Mitchell E Hughes; Robert H Vonderheide; David L Porter; Ran Reshef
Journal:  J Antimicrob Chemother       Date:  2015-04-16       Impact factor: 5.790

Review 5.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

6.  Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients.

Authors:  Yuichi Uwai; Satohiro Masuda; Maki Goto; Hideyuki Motohashi; Hideyuki Saito; Masahiro Okuda; Eijirou Nakamura; Noriyuki Ito; Osamu Ogawa; Ken-Ichi Inui
Journal:  J Hum Genet       Date:  2003-12-18       Impact factor: 3.172

Review 7.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging.

Authors:  Long Gu; Walter M Tsark; Donna A Brown; Suzette Blanchard; Timothy W Synold; Susan E Kane
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

9.  Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.

Authors:  Christian Friedrich; Stephan Glund; Dominick Lionetti; C James Kissling; Julian Righetti; Sanjay Patel; Ulrike Graefe-Mody; Silke Retlich; Hans-Juergen Woerle
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

Review 10.  ABC of oral bioavailability: transporters as gatekeepers in the gut.

Authors:  C G Dietrich; A Geier; R P J Oude Elferink
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.